Literature DB >> 26934504

Randomized clinical trial on 7-days-a-week post-operative radiotherapy vs concurrent post-operative radiochemotherapy in locally advanced cancer of the oral cavity/oropharynx: a report on acute normal tissue reactions.

Rafal Suwinski1, Grzegorz Wozniak2, Maciej Misiolek3, Magdalena Jaworska4, Maciej Kozaczka5, Wieslaw Bal5, Elzbieta Nowara5, Leszek Miszczyk2.   

Abstract

OBJECTIVE: The purpose of the study was to evaluate acute normal tissue reactions and treatment compliance in a randomized clinical trial on 7-days-a-week post-operative radiotherapy (p-CAIR) vs post-operative concurrent radiochemotherapy (p-RTCT) in locally advanced cancer of the oral cavity/oropharynx. The sample analyzed at present represents approximately 30% of the intended future trial size.
METHODS: The patients were randomly assigned to receive 63 Gy in 1.8-Gy fractions 7 days a week (n = 44) or 63 Gy in 1.8-Gy fractions 5 days a week with concurrent cisplatin 80-100 mg per square metre of body surface area on Days 1, 22 and 43 of the course of radiotherapy (n = 40). Acute mucosal reactions were scored using the modified Dische system.
RESULTS: 15 (17.9%) patients, including 5 patients in p-CAIR and 10 patients in p-RTCT, did not comply with the assigned radiation treatment, mostly because of rapid tumour progression or deteriorating general performance. In p-RTCT, 22 (55%) patients received less than the intended three courses of chemotherapy mostly owing to haematological toxicity. The average maximum mucosal severity score was 14.2 in p-CAIR compared with 13.4 in p-RTCT; the difference was not statistically significant (p = 0.31).
CONCLUSION: The schedules compared (p-CAIR and p-RTCT) did not differ considerably with respect to acute mucosal reactions. Haematological toxicity in p-RTCT was elevated compared with p-CAIR. Both schedules were considered tolerable with respect to acute toxicity, which justifies further recruitment to the trial. ADVANCES IN KNOWLEDGE: The results show that early mucosal reactions are comparable in both trial arms but haematological toxicity is more pronounced during radiochemotherapy.

Entities:  

Mesh:

Year:  2016        PMID: 26934504      PMCID: PMC4985452          DOI: 10.1259/bjr.20150805

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  14 in total

1.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

2.  Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.

Authors:  Rafal Suwinski; Magdalena Bankowska-Wozniak; Wojciech Majewski; Anna Sowa; Adam Idasiak; Ewa Ziolkowska; Wieslawa Windorbska; Rafal Tarnawski; Krzysztof Skladowski; Boguslaw Maciejewski
Journal:  Radiother Oncol       Date:  2005-09-12       Impact factor: 6.280

3.  Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity.

Authors:  B Maciejewski; K Skladowski; B Pilecki; J M Taylor; R H Withers; L Miszczyk; A Zajusz; R Suwinski
Journal:  Radiother Oncol       Date:  1996-08       Impact factor: 6.280

4.  The recording of morbidity related to radiotherapy.

Authors:  S Dische; M F Warburton; D Jones; E Lartigau
Journal:  Radiother Oncol       Date:  1989-10       Impact factor: 6.280

5.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.

Authors:  Krzysztof Skladowski; Boguslaw Maciejewski; Maria Golen; Rafal Tarnawski; Krzysztof Slosarek; Rafal Suwinski; Mariusz Sygula; Andrzej Wygoda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

6.  Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.

Authors:  Giuseppe Sanguineti; Antonella Richetti; Mario Bignardi; Renzo Corvo'; Pietro Gabriele; Maria Pia Sormani; Paolo Antognoni
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

7.  Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.

Authors:  Rafal Suwinski; Anna Sowa; Tomasz Rutkowski; Jerzy Wydmanski; Rafal Tarnawski; Boguslaw Maciejewski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

8.  Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial.

Authors:  L J Peters; H Goepfert; K K Ang; R M Byers; M H Maor; O Guillamondegui; W H Morrison; R S Weber; A S Garden; R A Frankenthaler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-30       Impact factor: 7.038

9.  Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer.

Authors:  Miroslaw Snietura; Wojciech Piglowski; Magdalena Jaworska; Anna Mucha-Malecka; Grzegorz Wozniak; Dariusz Lange; Rafal Suwinski
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-12       Impact factor: 2.503

10.  Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.

Authors:  H K Awwad; M Lotayef; T Shouman; A C Begg; G Wilson; S M Bentzen; H Abd El-Moneim; S Eissa
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  1 in total

1.  Randomised clinical trial on 7-days-a-week postoperative radiotherapy vs. concurrent postoperative radio-chemotherapy in locally advanced cancer of the oral cavity/oropharynx.

Authors:  Grzegorz Wozniak; Maciej Misiołek; Adam Idasiak; Iwona Dębosz-Suwińska; Magdalena Jaworska; Wieslaw Bal; Boguslaw Maciejewski; Leszek Miszczyk; Krzysztof Składowski; Rafal Suwinski
Journal:  Br J Radiol       Date:  2020-09-30       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.